NCT07295483Recruiting
Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)
To Analyze the Determining Factors in the Evolution of Subjects Diagnosed With Long COVID at Four Years of Follow-up. BioICOPER Follow-up Study.
Source: ClinicalTrials.gov · Last updated 12 Mar 2026
Brief summary (registry, in English)
Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking. The BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical symptomatology (particularly chronic fatigue) and vascular health after four years of follow-up among 400 participants previously included in the original BioICOPER cohort. Advanced proteomic analysis, vascular function assessment, and machine-learning-based predictive modeling will be used to identify biomarkers associated with disease progression, stratified by sex. This project will contribute to personalized clinical management of long COVID and improved diagnostic and therapeutic strategies in primary care.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 20 Nov 2025
- Start date
- 9 Feb 2026
- Primary completion date
- Mar 2029
- Lead sponsor
- Instituto de Investigación Biomédica de Salamanca
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT07295483
What you commit to
- Study type: Observational
- Planned participants: 400
- From 9 Feb 2026 to the primary completion date, Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Acute illness preventing participation.
- Cognitive or physical impairment limiting data collection.
Age
- Age \< 18 years old
Other
- Withdrawal of informed consent.
Who the study is looking for
- Adults ≥18 years old.
- Confirmed previous SARS-CoV-2 infection.
- Diagnosis of long COVID according to WHO criteria.
- Participation in the baseline BioICOPER study.
- Signed informed consent for re-evaluation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Av. de Portugal 83. Planta 2 Coordinator of this site? Confirm its status | Salamanca | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.